Company Zealand Pharma A/S

Equities

ZEAL

DK0060257814

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Zealand Pharma A/S

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:34 2024-04-19 am EDT			5-day change	1st Jan Change
583.5 ^DKK	-2.42%		-1.02%	+56.35%

Apr. 04	U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year	DJ
Mar. 20	Zealand Pharma A/S Approves Appointments to the Board	CI

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.

At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.

Number of employees: 253

DKK in Million	2022	Weight	2023	Weight	Delta
Peptide-based Medicines 100.0 %	104	100.0 %	343	100.0 %	+229.65%

DKK in Million	2022	Weight	2023	Weight	Delta
Germany 85.9 %	-	-	294,509	85.9 %	-
Denmark 12.9 %	35	33.7 %	44,185	12.9 %	+126,142.86%
United States 1.2 %	69	66.3 %	4,094	1.2 %	+5,833.33%

Managers	Title	Age	Since
Adam Sinding Steensberg CEO	Chief Executive Officer	50	09-12-31
Henriette Wennicke DFI	Director of Finance/CFO	-	22-10-31
Ivan M. Møller COO	Chief Operating Officer	52	18-02-28
David M. Kendall CTO	Chief Tech/Sci/R&D Officer	62	22-06-01
Frederik Barfoed Beck BRD	Director/Board Member	57	-
Anna Krassowska IRC	Investor Relations Contact	-	-
Ravinder Chahil LAW	General Counsel	56	-
Christina Sonnenborg Bredal HRO	Human Resources Officer	39	19-12-31

Members of the board	Title	Age	Since
Leonard Kruimer BRD	Director/Board Member	66	19-04-03
Alf Gunnar Martin Nicklasson CHM	Chairman	69	14-12-31
Kirsten Drejer BRD	Director/Board Member	68	18-04-18
Jeffrey Berkowitz BRD	Director/Board Member	58	19-04-03
Bernadette Connaughton BRD	Director/Board Member	65	19-04-03
Frederik Barfoed Beck BRD	Director/Board Member	57	-
Anneline Nansen BRD	Director/Board Member	55	21-08-31

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	62,648,011	62,176,860 ( 99.25 %)	373,134 ( 0.5956 %)	99.25 %

Name	Equities	%	Valuation
Van Herk Investments BV 9.955 %	6,233,183	9.955 %	616 M kr
Polar Capital LLP 9.019 %	5,647,561	9.019 %	558 M kr
J.O. Hambro Capital Management Ltd. 4.996 %	3,128,162	4.996 %	309 M kr
MP Investment Management A/S 4.176 %	2,614,590	4.176 %	258 M kr
Nykredit Bank A/S (Investment Management) 0.9978 %	624,778	0.9978 %	62 M kr
ZEALAND PHARMA A/S 0.5959 %	373,134	0.5959 %	37 M kr
Fundamental Fondsmæglerselskab A/S 0.4956 %	310,340	0.4956 %	31 M kr
Banque Internationale À Luxembourg SA (Denmark) 0.4380 %	274,263	0.4380 %	27 M kr
Danske Bank A/S (Investment Management) 0.4293 %	268,796	0.4293 %	27 M kr
Union Investment Privatfonds GmbH 0.2694 %	168,666	0.2694 %	17 M kr

Name	Equities	%	Valuation
ZEALAND PHARMA A/S 0.60%	373,134	0.60%	36,890,098 $

Zealand Pharma A/S

Sydmarken 11

2860, Soborg

+45 88 77 36 00

http://www.zealandpharma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

583.5 DKK

Average target price

754.3 DKK

Spread / Average Target

+29.27%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ZEALAND PHARMA A/S	+56.35%	5.32B
VERTEX PHARMACEUTICALS INCORPORATED	-3.10%	102B
REGENERON PHARMACEUTICALS, INC.	+2.11%	96.07B
ARGENX SE	-1.80%	21.66B
BIONTECH SE	-17.75%	20.77B
GENMAB A/S	-6.91%	18.53B
WUXI APPTEC CO., LTD.	-42.00%	16.91B
BEIGENE, LTD.	-28.19%	13.79B
NEUROCRINE BIOSCIENCES, INC.	+0.18%	13.33B
SAREPTA THERAPEUTICS, INC.	+19.90%	10.94B

Bio Therapeutic Drugs